PharmiWeb.com - Global Pharma News & Resources

Medical comms - Press Releases

Date Title Company
26-Apr-2024 Stockholm, Sweden – April 26 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces the appointment of Anna Asplind as Phase 3 Program Manager. OncoZenge
26-Apr-2024 HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda HUTCHMED
26-Apr-2024 Liebherr presents its innovative cooling solutions at Clinical Pharmacy Congress 2024 Liebherr
26-Apr-2024 eyeDNA Therapeutics to Present 2-year Follow-up Phase I/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting eyeDNA Therapeutics
25-Apr-2024 Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024 Heidelberg Pharma
25-Apr-2024 BIAL appoints Pierluigi Antonelli as Non-Executive Board Member BIAL
25-Apr-2024 V-Bio Ventures leads €20 million Series A financing of Precision oncology company Flindr Therapeutics to advance first-in-class small molecule inhibitors V-Bio Ventures
25-Apr-2024 Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development Cambridge Cognition
25-Apr-2024 New £40M research centres will unlock new tests, treatments and cures for people living with rare diseases LifeArc
25-Apr-2024 LifeArc launches £40M research centres that will unlock new tests, treatments and cures for people living with rare diseases LifeArc
23-Apr-2024 AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting AAVantgarde Bio
23-Apr-2024 CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy Janssen-Cilag International NV,
23-Apr-2024 BenevolentAI provides an update on its business priorities BenevolentAI
23-Apr-2024 Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development Cambridge Cognition Holdings plc
23-Apr-2024 MPE launches the Myeloma and AL Amyloidosis European Clinical Trial Navigator Myeloma Patients Europe (MPE)
21-Apr-2024 Agenda Announced for Semantic Data 2024: Taxonomy, Ontology, and Knowledge Graphs conference in London Henry Stewart Events
18-Apr-2024 Beckman Coulter Life Sciences Launches QbD1200+ Total Organic Carbon Analyzer Beckman Coulter Life Sciences
18-Apr-2024 BC Platforms and NTT Group Announce Official Opening Ceremony for Exclusive Collaboration and Launch of Japanese Precision Medicine Platform BC Platforms (BCP)
11-Apr-2024 AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock AdrenoMed AG
11-Apr-2024 Sanofi announces launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for pre-exposure and post-exposure prophylaxis of rabies in all age groups Sanofi